FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890135386> ?p ?o ?g. }

• W2890135386 abstract "Androgen-deprivation therapy (ADT) remains the gold-standard therapy for prostate cancer (PrCa), and although ADT is initially effective, most men progress to castrate-resistant prostate cancer (CRPC) within 2-3 years. Advanced CRPC is challenging to treat because intrinsic tumor heterogeneity and phenotypic plasticity engender short-lived responses and underlie resistance to conventional therapies. Combined PTEN/TP53 alterations represent a major genotype of advanced CRPC (25-30%) and are associated with poor clinical outcomes. Established PrCa cell lines do not accurately represent the heterogeneity of advanced CRPC, and therefore, nonbiased pharmacogenomics screens have not been done. The development of clinically representative, tractable models suitable for high-throughput target identification and validation is crucial for advancing novel CRPC therapies to the clinic. A comprehensive nonbiased high-throughput screen performed on seven cell lines derived from a genetically engineered mouse model (GEMM) of Pten/Tp53 null PrCa identified strongly active compounds, including inhibitors of PI3K/AKT/mTOR signaling, the proteasome, cell cycle regulatory proteins, heat shock proteins, DNA repair signaling, NFKB signaling, MAPK signaling, and several types of epigenetic modifiers. HSP90 inhibitors were one of the most efficacious classes of compounds in the screen, and ganetespib, a clinically used second-generation HSP90 inhibitor with a favorable safety profile, was the most potent. Although HSP90 inhibitors have yet to be successful as single agents, they have not been thoroughly investigated in clinically representative models of advanced PrCa and have shown potential as “network drugs,” prompting our investigations into their utility in polytherapy. We first validated ganetespib as a single agent, where it displayed strong activity against several GEMM-derived and LuCaP PDX-derived organoid models encompassing genotypic, phenotypic, and lineage heterogeneity. These 10 novel LuCaP PDX-derived organoids are representative of the numerous categories of CRPC, including adenocarcinomas with wild-type AR, adenocarcinomas with altered AR, adenocarcinoma with neuroendocrine features, and neuroendocrine disease. Single-agent ganetespib was also strongly inhibitory in vivo, decreasing growth of Pten/Tp53 null endogenous GEMM tumors as well as a human PDX tumor. Mechanistic interrogation of cell lines, organoids, and tumors exposed to ganetespib revealed inhibition of targets from several inter-related networks including AR and pAKT, two central and mutually compensatory growth and survival pathways for PrCa. The efficacy of ganetespib against a diverse group of CRPC organoids and the simultaneous inhibition of PrCa survival signaling suggested it may work well in combination. We performed a proof-of-principle high-throughput matrix screen on organoids derived from a Pten/Tp53 null GEMM and identified docetaxel and etoposide to be synergistic when combined with ganetespib. Preclinical in vivo studies to validate these findings are ongoing. In all, comprehensive data from multiple near-patient models suggest novel contexts for second-generation HSP90-directed intervention against a variety of CRPC genotypes and phenotypes and expand upon the potential of HSP90 inhibitors to simultaneously inhibit oncogenic signaling and compensatory resistance mechanisms. Citation Format: Keith H. Jansson, John B. Tucker, Lauren E. Stahl, John K. Simmons, Caitlyn Fuller, Michael L. Beshiri, Supreet Agarwal, Yasmine Abbey, Lei Fang, Paul G. Hynes, Alilin Aian Neil, Jacob Cawley, Ross Lake, Crystal Tran, Caitlin M. Tice, JuanJuan Yin, Xiahu Zhang, Rajarshi Guha, Shelley Hoover, R. Mark Simpson, Holly Nguyen, Eva Corey, Craig J. Thomas, David Proia, Kathleen Kelly. A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr B018." @default.
• W2890135386 created "2018-09-27" @default.
• W2890135386 creator A5002466627 @default.
• W2890135386 creator A5009972842 @default.
• W2890135386 creator A5014278257 @default.
• W2890135386 creator A5014462897 @default.
• W2890135386 creator A5015195078 @default.
• W2890135386 creator A5015713542 @default.
• W2890135386 creator A5018745405 @default.
• W2890135386 creator A5022088555 @default.
• W2890135386 creator A5025720503 @default.
• W2890135386 creator A5030186057 @default.
• W2890135386 creator A5042566684 @default.
• W2890135386 creator A5051333815 @default.
• W2890135386 creator A5052330723 @default.
• W2890135386 creator A5057136166 @default.
• W2890135386 creator A5057196078 @default.
• W2890135386 creator A5063654781 @default.
• W2890135386 creator A5065454179 @default.
• W2890135386 creator A5069062997 @default.
• W2890135386 creator A5072277158 @default.
• W2890135386 creator A5074453210 @default.
• W2890135386 creator A5080283192 @default.
• W2890135386 creator A5083596371 @default.
• W2890135386 creator A5084127233 @default.
• W2890135386 creator A5087164643 @default.
• W2890135386 creator A5087219811 @default.
• W2890135386 date "2018-08-14" @default.
• W2890135386 modified "2023-10-06" @default.
• W2890135386 title "Abstract B018: A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancer" @default.
• W2890135386 doi "https://doi.org/10.1158/1538-7445.prca2017-b018" @default.
• W2890135386 hasPublicationYear "2018" @default.
• W2890135386 type Work @default.
• W2890135386 sameAs 2890135386 @default.
• W2890135386 citedByCount "0" @default.
• W2890135386 crossrefType "proceedings-article" @default.
• W2890135386 hasAuthorship W2890135386A5002466627 @default.
• W2890135386 hasAuthorship W2890135386A5009972842 @default.
• W2890135386 hasAuthorship W2890135386A5014278257 @default.
• W2890135386 hasAuthorship W2890135386A5014462897 @default.
• W2890135386 hasAuthorship W2890135386A5015195078 @default.
• W2890135386 hasAuthorship W2890135386A5015713542 @default.
• W2890135386 hasAuthorship W2890135386A5018745405 @default.
• W2890135386 hasAuthorship W2890135386A5022088555 @default.
• W2890135386 hasAuthorship W2890135386A5025720503 @default.
• W2890135386 hasAuthorship W2890135386A5030186057 @default.
• W2890135386 hasAuthorship W2890135386A5042566684 @default.
• W2890135386 hasAuthorship W2890135386A5051333815 @default.
• W2890135386 hasAuthorship W2890135386A5052330723 @default.
• W2890135386 hasAuthorship W2890135386A5057136166 @default.
• W2890135386 hasAuthorship W2890135386A5057196078 @default.
• W2890135386 hasAuthorship W2890135386A5063654781 @default.
• W2890135386 hasAuthorship W2890135386A5065454179 @default.
• W2890135386 hasAuthorship W2890135386A5069062997 @default.
• W2890135386 hasAuthorship W2890135386A5072277158 @default.
• W2890135386 hasAuthorship W2890135386A5074453210 @default.
• W2890135386 hasAuthorship W2890135386A5080283192 @default.
• W2890135386 hasAuthorship W2890135386A5083596371 @default.
• W2890135386 hasAuthorship W2890135386A5084127233 @default.
• W2890135386 hasAuthorship W2890135386A5087164643 @default.
• W2890135386 hasAuthorship W2890135386A5087219811 @default.
• W2890135386 hasConcept C104317684 @default.
• W2890135386 hasConcept C121608353 @default.
• W2890135386 hasConcept C126322002 @default.
• W2890135386 hasConcept C205260736 @default.
• W2890135386 hasConcept C2775932338 @default.
• W2890135386 hasConcept C2777560012 @default.
• W2890135386 hasConcept C2777609662 @default.
• W2890135386 hasConcept C2780192828 @default.
• W2890135386 hasConcept C41091548 @default.
• W2890135386 hasConcept C502942594 @default.
• W2890135386 hasConcept C54355233 @default.
• W2890135386 hasConcept C60644358 @default.
• W2890135386 hasConcept C62478195 @default.
• W2890135386 hasConcept C71924100 @default.
• W2890135386 hasConcept C86554907 @default.
• W2890135386 hasConcept C86803240 @default.
• W2890135386 hasConcept C95444343 @default.
• W2890135386 hasConceptScore W2890135386C104317684 @default.
• W2890135386 hasConceptScore W2890135386C121608353 @default.
• W2890135386 hasConceptScore W2890135386C126322002 @default.
• W2890135386 hasConceptScore W2890135386C205260736 @default.
• W2890135386 hasConceptScore W2890135386C2775932338 @default.
• W2890135386 hasConceptScore W2890135386C2777560012 @default.
• W2890135386 hasConceptScore W2890135386C2777609662 @default.
• W2890135386 hasConceptScore W2890135386C2780192828 @default.
• W2890135386 hasConceptScore W2890135386C41091548 @default.
• W2890135386 hasConceptScore W2890135386C502942594 @default.
• W2890135386 hasConceptScore W2890135386C54355233 @default.
• W2890135386 hasConceptScore W2890135386C60644358 @default.
• W2890135386 hasConceptScore W2890135386C62478195 @default.
• W2890135386 hasConceptScore W2890135386C71924100 @default.
• W2890135386 hasConceptScore W2890135386C86554907 @default.
• W2890135386 hasConceptScore W2890135386C86803240 @default.
• W2890135386 hasConceptScore W2890135386C95444343 @default.
• W2890135386 hasLocation W28901353861 @default.
• W2890135386 hasOpenAccess W2890135386 @default.
• W2890135386 hasPrimaryLocation W28901353861 @default.
• W2890135386 hasRelatedWork W1005262890 @default.
• W2890135386 hasRelatedWork W2025319771 @default.

• next